Phase I SBIR grant from the National Institute of Arthritis

Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will support the translation platform technology to generate long-acting drug products that can be used to treat inflammatory joint diseases.